The research, published in the British Journal of Pharmacology, highlights these non-intoxicating cannabinoids' potential to significantly reduce liver fat and improve metabolic health in experimental models.
A New Path for Treating Liver Disease
The study reveals a process called 'metabolic remodeling,' in which CBD and CBG create a 'backup battery' for the liver by increasing phosphocreatine levels, an unexpected discovery that helps the organ function under high-fat diet stress.
Additionally, the compounds restore the activity of 'cellular cleaning crews' known as cathepsins, enabling the liver to clear out dangerous lipids, including triglycerides and ceramides, which trigger inflammation.
Promising Results with Caution
While both compounds were effective, CBG showed more robust results in certain areas, such as reducing body weight, lowering 'bad' LDL cholesterol, and improving insulin sensitivity.
Researchers emphasize that further clinical trials are necessary to determine the proper application for treating MASLD.
Cannabis in Medical Research
A recent JAMA analysis highlighted significant gaps between public perception and scientific evidence regarding cannabis' effectiveness for most medical conditions.
The strongest evidence supports FDA-approved cannabinoid medications for treating specific conditions, including HIV/AIDS-related appetite loss, chemotherapy-induced nausea and vomiting, and certain severe pediatric seizure disorders.
Individuals interested in using marijuana for medical purposes should consult healthcare professionals to discuss potential risks and benefits.